Transplanting hepatitis C-positive kidneys

New England Journal of Medicine

Volumn 373, Issue 4, 2015, Pages 303-305

  Reese, Peter P ^a,b   Abt, Peter L ^b   Blumberg, Emily A ^c   Goldberg, David S ^b,d  

^a Renal Electrolyte and Hypertension Division   (United States)

^b Department of Biostatistics and Epidemiology ^*  (United States)

^c Divisions of Infectious Diseases   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST CONTROL; GRAFT SURVIVAL; HEALTH CARE COST; HEPATITIS C; HUMAN; INFORMED CONSENT; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MEDICAL DECISION MAKING; MORTALITY; PATIENT AUTONOMY; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIRUS TRANSMISSION; ADVERSE EFFECTS; COMPLICATION; HEPACIVIRUS; ISOLATION AND PURIFICATION; KIDNEY; VIROLOGY;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; INFORMED CONSENT; KIDNEY; KIDNEY TRANSPLANTATION;

EID: 84937917395     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1505074     Document Type: Article

References (5)

1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipas-vir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
2. Schnitzler MA, Lentine KL, Burroughs TE. The cost effectiveness of deceased organ do-nation. Transplantation 2005;80:1636-7.
3. Abbott KC, Bucci JR, Matsumoto CS, et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003;14:2908-18.
4. Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Under-utilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant 2010;10:1238-46.
5. Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: preliminary results of a prospective, multicenter study. Hepatol-ogy 2014;60:200A. abstract.